Optibrium and NextMove Software Announce Technology Collaboration
News Jan 16, 2015
Optibrium™ and NextMove Software have announced an agreement to collaborate on the integration of NextMove Software’s Matsy technology with Optibrium’s StarDrop software suite. The combination of these technologies will help guide scientists to quickly identify novel compounds based on matched molecular series analysis with a high chance of success for their drug discovery projects.
The Matsy algorithm has been developed by NextMove Software to generate and search databases of matched molecular series to identify chemical substitutions that are most likely to improve target activity (J. Med. Chem., 2014, 57(6), pp 2704-2713). This goes beyond conventional ‘matched molecular pair analysis’ by using data from longer series of matched compounds (and not just pairs) to make more relevant predictions for a particular chemical series of interest.
As part of the collaboration with Optibrium, Matsy will be applied in StarDrop’s Nova™ module, which automatically generates new compound structures to stimulate the search for optimization strategies related to initial hit or lead compounds. StarDrop’s unique capabilities for multi-parameter optimization and predictive modelling will enable efficient prioritization of the resulting ideas to identify high quality compounds with the best chance of success.
Dr Matthew Segall, Optibrium’s CEO, commented: “We are delighted to announce our collaboration with NextMove Software, which has a proven track record of developing innovative informatics solutions for pharma companies world-wide. We remain committed to working with NextMove and our other partners to provide access to the leading compound optimization technologies through StarDrop’s unique environment that guides efficient discovery of novel, high quality drugs.”
Dr Roger Sayle, CEO of NextMove Software added “We are excited to be working together with Optibrium to combine the Matsy technology with StarDrop’s intuitive interface for compound generation.”
The results of this collaboration will be available in a future version of StarDrop, expected to be released during 2015.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Allergy Amplifier Implicated in Asthma Also Intensifies Food AllergyNews
Scientist who previously reported that a small protein, aptly named histamine-releasing factor, played a pro-inflammatory role in asthma have now shown that it also serves as a “food allergy amplifier”. This work paves the way for blood tests to predict which patients will respond to allergy therapy, and strongly supports the idea that drugs designed to block HRF could prevent food allergy attacks.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE